PNC-27 10 MG

Dragon Pharma PNC-27 10 mg – Experimental Peptide for Cancer Cell Necrosis Research

Dragon Pharma PNC-27 10 mg is an experimental synthetic peptide consisting of 32 amino acids that has been studied for its anti-cancer properties in laboratory settings. This peptide combines a fragment of the p53 tumor suppressor protein with a cell-penetrating sequence, creating a compound designed to specifically target cancer cells while leaving healthy cells unaffected.

Each vial contains 10 mg of lyophilized PNC-27 in a 2 mL format, requiring reconstitution with bacteriostatic water before use. The unique mechanism of PNC-27 involves targeting HDM-2 proteins on cancer cell membranes, resulting in pore formation and subsequent cell death through necrosis. For related research compounds, explore our peptides category and specifically FOXO4-DRI for studies on cellular senescence.

What Makes PNC-27 Valuable in Research?

PNC-27 represents a unique approach to cancer research through its selective targeting mechanism. By combining the p53 fragment with a cell-penetrating sequence, this peptide is designed to interact specifically with HDM-2 proteins present on cancer cell membranes. This interaction triggers pore formation, leading to rapid cell death through necrosis while demonstrating selectivity for cancer cells over normal cells.

Researchers value PNC-27 for its novel mechanism of action and its potential to provide insights into cancer cell biology. Its ability to induce necrosis specifically in cancer cells makes it a valuable tool for investigating cancer cell vulnerability and developing new therapeutic strategies. For investigators exploring other mechanisms of cellular regulation, Epitalon 50 mg offers complementary research avenues in cellular health and longevity.

Current scientific literature on PNC-27 can be accessed through the PubMed database, where researchers can review peer-reviewed studies on its biological activity and experimental applications.

Key Research Applications for Dragon Pharma PNC-27

• ✔ Investigation of cancer cell death mechanisms
• ✔ Evaluation of HDM-2 targeting and pore formation
• ✔ Research on cancer cell selectivity and normal cell sparing
• ✔ Studies of necrosis pathways in cancer models
• ✔ Preclinical models of anti-cancer activity

Product Details

Dosage & Usage Guidelines

Reconstitution Protocol

• ✔ Use sterile bacteriostatic water for injection
• ✔ Add appropriate volume to achieve desired concentration
• ✔ Swirl gently to dissolve – do not shake vigorously
• ✔ Store reconstituted solution at 2–8°C

Reconstitute the lyophilized powder using bacteriostatic water to a concentration suitable for your research protocol. The 10 mg format allows for flexible dosing across a range of experimental models. Always use aseptic technique during preparation to maintain peptide integrity.

Typical Research Parameters

In research settings, PNC-27 is typically administered via subcutaneous or intravenous injection in experimental models. Dosing schedules and concentrations vary widely depending on the experimental design, cell line, or animal model, and specific research objectives.

• ✔ Commonly used in cancer cell line studies
• ✔ Often combined with cell viability and apoptosis assays
• ✔ Used to investigate cancer cell membrane interactions
• ✔ Research models include various cancer cell types and xenograft studies

Factors to Consider in Research Protocols

• Specific targeting of HDM-2 requires careful dose optimization
• Reconstitution stability is limited; prepare fresh solutions for each use
• Individual variation in response may be observed across cell lines
• Storage conditions significantly impact peptide stability

Lab Testing & Batch Transparency

Lab status

COA pending release

Third-party analytical testing (COA) for Dragon Pharma PNC-27 10 mg is currently not yet available. Batch-specific assay data, purity analysis, and verification documentation will be published once released.

Testing Status

Pending

COA Availability

Not yet published

Batch Verification

In progress

Update

Coming soon

Transparency note: Dragon Pharma publishes batch-specific lab reports once analytical testing is completed and verified.

Awaiting COA

Shipping & Product Authenticity

What to Expect

• ✔ Orders are processed after payment confirmation
• ✔ USA Domestic shipping is typically faster when local stock is selected
• ✔ International orders include tracking, though update frequency may vary by destination
• ✔ Multiple warehouses may result in separate shipments when applicable

For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.

Storage

Store the lyophilized powder at controlled room temperature (15–25°C) in a dry, dark place, away from direct light and moisture. The unopened vial should be kept in its original packaging to maintain stability.

After reconstitution, store the solution at 2–8°C and use within 14 days. Do not freeze. Discard any unused portion after the recommended storage period. Before use, inspect the solution and avoid use if it appears cloudy, discolored, or contains particulate matter, or if the vial or seal is compromised.

Keep out of reach of children. Follow proper handling and sterile injection practices during research use.

Proper storage conditions help maintain product stability and consistent performance across the product's shelf life.

Frequently Asked Questions